An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M6620 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors

Trial Profile

An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M6620 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs M 6620 (Primary) ; Cisplatin; Etoposide; Gemcitabine
  • Indications Advanced breast cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 12 Sep 2017 Initial results (n=35 females) assessing safety and efficacy of M6620 in combination with cisplatin in metastatic triple negative breast cancer patients presented at the 42nd European Society for Medical Oncology Congress
    • 14 Aug 2017 Planned End Date changed from 1 Jul 2017 to 1 Jan 2018.
    • 14 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top